Rachel Conyers, paediatric oncologist, Director of Children’s Cancer Centre at the The Royal Children’s Hospital and Professor at the University of Melbourne, shared a post on linkedIn:
“Here’s a question nobody in paediatric oncology is asking loudly enough:
Do neurodivergent children with leukaemia experience adverse drug reactions differently?
The ADR burden in childhood cancer is already significant. The neurobiology of ADHD and autism affects how kids process, tolerate and respond to pharmacological treatment.
Yet the intersection of neurodiversity and chemotherapy toxicity is almost entirely uncharted.
This is a gap. It’s also an opportunity — to do research that could directly change how we treat some of our most vulnerable patients.
If this is your space too, I’d like to hear from you.”
Other articles about Childhood Cancer on OncoDaily.